P/E ratio for Biomerica (BMRA)
P/E ratio as of May 2024 (TTM): -1.25
According to Biomerica's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.25149. At the end of 2022 the company had a P/E ratio of -7.79.
P/E ratio history for Biomerica from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -7.79 | 4.14% |
| 2021 | -7.48 | -29.4% |
| 2020 | -10.6 | -12.29% |
| 2019 | -12.1 | 56.33% |
| 2018 | -7.73 | -73.14% |
| 2017 | -28.8 | 162.68% |
| 2016 | -11.0 | |
| 2014 | -24.4 | 56.73% |
| 2013 | -15.6 | -304.29% |
| 2012 | 7.64 | 11.36% |
| 2011 | 6.86 | -116.33% |
| 2010 | -42.0 | 2.44% |
| 2009 | -41.0 | -1125% |
| 2008 | 4.00 | -43.23% |
| 2007 | 7.05 | 5.68% |
| 2006 | 6.67 | -16.67% |
| 2005 | 8.00 | |
| 2003 | -11.3 | 183.93% |
| 2002 | -3.96 | 98.11% |
| 2001 | -2.00 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Align Technology
ALGN | 60.8 | -4,954.60% | 🇺🇸 USA |
 Dentsply Sirona
XRAY | -28.3 | 2,157.31% | 🇺🇸 USA |
 Biolase
BIOL | -0.0007 | -99.95% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.